Abstract:Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the digestive tract with malignant potential. The current risk classification standard is unable to accurately evaluate the invasiveness and clinical outcomes of GISTs. Ki-67 labelling index (LI) may be an effective indicator in assessing tumour invasiveness and prognosis, however, its exact value in GISTs is still uncertain. The aims of our study were to evaluate the correlation of the Ki-67 LI and clinicopathological features of GISTs and to assess the potential value of the Ki-67 LI in GISTs classification and prognosis. The clinical, pathological and prognostic data were collected and analysed to identify the independent influential factors of GISTs risk stratification and the predictors of GISTs prognosis. The Ki-67 LI was significantly associated with the clinicopathological features of tumour progression (P< 0.05). It was an independent influential factor of GISTs risk classification (odds ratio: 1.322; 95% confidence interval: 1.031-1.696) (P = 0.028), and the area under the curve (AUC) value of the Ki-67 LI on the discrimination ability of GISTs risk stratification was 0.906 (P< 0.001). The optimal cutoff value of the Ki-67 LI was 6% (sensitivity of 87.5% and specificity of 76.2%), and patients with Ki-67 LI≥6% exhibited significantly poorer progression-free survival (PFS) than those with Ki-67 LI< 6% (P< 0.001). The AUC value of the Ki-67 LI for predicting PFS in postoperative patients was 0.813 (P = 0.03). The Ki-67 LI has appreciated value to predict the risk grade and prognosis of GISTs. Patients with Ki-67 LI≥6% are prone to recurrence and metastasis after operation and may need a close follow-up. Los tumores del estroma gastrointestinal (TEGI) son los tumores mesenquimatosos más frecuentes del tubo digestivo con capacidad maligna. Las pautas actuales de clasificación del riesgo no permiten evaluar con precisión la invasividad y los resultados clínicos de los TEGI. El índice de proliferación celular (IPC) Ki-67 puede ser un indicador eficaz para evaluar la invasividad y el pronóstico del tumor, pero todavía existe incertidumbre respecto a su valor exacto en los TEGI. Los objetivos de nuestro estudio fueron evaluar la correlación del IPC Ki-67 y las características clinicopatológicas de los TEGI y evaluar el posible valor del IPC Ki-67 en la clasificación y el pronóstico de los TEGI. Se recopilaron y analizaron los datos clínicos, anatomopatológicos y pronósticos para identificar los factores influyentes independientes de la estratificación del riesgo de los TEGI y los factores predictivos del pronóstico de los TEGI. El IPC Ki-67 se asoció de manera significativa a las características clinicopatológicas de la progresión tumoral (p < 0,05). Fue un factor influyente independiente de la clasificación del riesgo de los TEGI (oportunidad relativa: 1,322; intervalo de confianza del 95%: 1,031-1,696) (p = 0,028), y el valor del área bajo la curva (AUC) del IPC Ki-67 sobre la capacidad de discriminación de la estratificación del riesgo de los TEGI fue de 0,906 (p < 0,001). El valor óptimo de corte del IPC Ki-67 fue del 6% (sensibilidad del 87,5% y especificidad del 76,2%), y los pacientes con un IPC Ki-67 ≥ 6% mostraron una supervivencia sin progresión (SSP) significativamente peor que aquellos con IPC Ki-67 < 6% (p < 0,001). El valor AUC del IPC Ki-67 para predecir la SSP en los pacientes postoperatorios fue de 0,813 (p = 0,03). El IPC Ki-67 tiene un gran valor para predecir el grado de riesgo y el pronóstico de los TEGI. Los pacientes con IPC Ki-67 ≥ 6% son propensos a la recidiva y metástasis después de una operación y pueden necesitar un estricto seguimiento.

Ki-67 Labeling Index May Be a Promising Indicator to Identify "very High-Risk" Gastrointestinal Stromal Tumor: a Multicenter Retrospective Study of 1022 Patients.

Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs)

Expression of Ki-67 in Moderate and High Risk Gastrointestinal Stromal Tumors with CD117 Immunoreactive

Prognostic value of Ki67 index in gastrointestinal stromal tumors.

Prognostic Significance of PTEN, Ki-67 and CD44s Expression Patterns in Gastrointestinal Stromal Tumors

Ki-67 Labelling Index is Related to the Risk Classification and Prognosis of Gastrointestinal Stromal Tumours: a Retrospective Study

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

The Relationship Between Ki-67 Expression and Imaging Signs and Pathological Features in GISTs.

Evaluation of Malignancy Using Ki-67, P53, Egfr and Cox-2 Expressions in Gastrointestinal Stromal Tumors

Utility of preoperative computed tomography features in predicting the Ki-67 labeling index of gastric gastrointestinal stromal tumors

Expressions and prognostic value of EGFR, COX-2, Ki-67, and p53 in gastrointestinal stromal tumors

A Correlation Research of Ki67 Index, CT Features, and Risk Stratification in Gastrointestinal Stromal Tumor

Tumor Sites and Microscopic Indicators Are Independent Prognosis Predictors of Gastrointestinal Stromal Tumors

Risk Stratification of Gastrointestinal Stromal Tumors: Are Imaging Findings and Histopathological Features Correlated?

Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.

[Relationship Between Expression of Cyclin D1, Ki-67 and Bcl-2 and Biologic Behavior in CD117-positive Gastrointestinal Stromal Tumors].

Clinicopathological analysis of gastrointestinal stromal tumor with CD_(117) positive staining and its significances

Expression of p53、Ki-67、Bcl-2 and CyclinD1 in Gastrointestinal Stromal Tumors and Their Correlation with the Prognosis of Stromal Tumors

A Novel Pathological Prognostic Score (PPS) to Identify "very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST).

Gastrointestinal Stromal Tumor and Ki-67 as a Prognostic Indicator

A New Nomogram for Recurrence-Free Survival Prediction of Gastrointestinal Stromal Tumors: Comparison with Current Risk Classification Methods